◀ Back to IL6

IL6 — NPEPPS

Text-mined interactions from Literome

Okamoto et al., Immunopharmacology 2000 : In in vitro experiments using human peripheral blood mononuclear cells ( PBMC ), OK-PSA induced IFN-gamma, interleukin (IL)-2 , IL-12, IL-18, tumor necrosis factor (TNF)-alpha and TNF-beta that are generally called `` Th1-type cytokines '' both in protein and in mRNA levels
Lin et al., Clin Cancer Res 2001 (Prostatic Neoplasms) : We found that in the absence of androgen, IL-6 increased prostate-specific antigen (PSA) mRNA levels and activated several androgen-responsive promoters, but not the non-androgen responsive promoters in LNCaP cells ... These data indicate the IL-6 induces an androgen response in CaP cells through the AR. Pretreatment of LNCaP cells with SB202190, PD98059, or tyrphostin AG879 [ p38 mitogen activated protein kinase ( MAPK ), MAP/extracellular signal regulated protein kinase kinase 1/2, and ErbB2 MAPK inhibitors, respectively ) but not wortmannin ( PI3-kinase inhibitor ) blocked IL-6 mediated induction of the PSA promoter, which demonstrates that IL-6 activity is dependent on a MAPK pathway
Oshikawa et al., Int Immunopharmacol 2003 (Neoplasms) : In the in vitro experiments using human peripheral blood mononuclear cells ( PBMCs ), OK-PSA markedly induced Th1-type cytokines, while interleukin (IL)-6 and IL-10, Th2-type cytokines, were induced by OK-PTF
Ikezoe et al., Cancer Sci 2004 (Prostatic Neoplasms) : In addition, we found that PS-341 down-regulated both 5alpha-dihydrotestosterone ( DHT ) - and interleukin-6 (IL-6) induced expression of prostate-specific antigen (PSA) as measured by western blot analysis
Debes et al., Cancer Res 2005 (Prostatic Neoplasms) : In this regard, we have shown previously that the coactivator p300 plays a major role in the androgen independent activation of PSA by interleukin 6 (IL-6) , a cytokine involved in late-stage prostate cancer